Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma

Cancer

Volumn 92, Issue 3, 2001, Pages 601-608

  White, Shane C ^a,b   Lorigan, Paul ^a,b   Middleton Heather Anderson, Mark R ^a,b   Valle, Juan ^a,b   Summers, Yvonne ^a,b   Burt, Paul A ^a,b   Arance, Ana ^a,b   Stout, Ron ^a,b   Thatcher, Nick ^a,b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

Carboplatin; Chemotherapy; Lung carcinoma; Poor prognosis; Toxicity

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; VINCRISTINE;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DYSPNEA; FEMALE; HUMAN; INFECTION RISK; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SEPSIS; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SMALL CELL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 0035425262     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010801)92:3<601::AID-CNCR1360>3.0.CO;2-K     Document Type: Article

References (27)

1. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer
2. Longevity in small cell lung cancer. A report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research
3. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients
4. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research
5. Small-cell carcinoma of the lung: Derivation of a prognostic staging system
6. Predicting septic complications of chemotherapy: An analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis
7. Patients at risk of chemotherapy-associated toxicity in small cell lung cancer
8. A randomised trial of low-dose/high-frequency chemotherapy as palliative treatment of poor-prognosis small-cell lung cancer: A Cancer Research Campaign trial
9. Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis
10. A randomized trial of two etoposide schedules in small-cell lung cancer: The influence of pharmacokinetics on efficacy and toxicity
11. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped multicentre randomised trial
12. Five-day oral etoposide treatment for advanced small-cell lung cancer: Randomized comparison with intravenous chemotherapy
13. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study
14. Carboplatin: A very active new cisplatin analog in the treatment of small cell lung cancer
15. Carboplatin in small cell lung cancer
16. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum
17. Carboplatin in the treatment of advanced breast cancer: A Phase II study using a pharmacokinetically guided dose schedule
18. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
19. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer
20. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A Phase III trial of the Southeastern Cancer Study Group
21. Small cell lung cancer: Patients included in clinical trials are not representative of the patient population as a whole
22. Treatment-related deaths in small cell lung cancer trials: Can patients at risk be identified?
23. Comparison of cyclophosphamide, doxorubicin, and vincristine with an alternating regimen of methotrexate, etoposide, and cisplatin/cyclophosphamide, doxorubicin, and vincristine in the treatment of extensive-disease small-cell lung carcinoma: A Mid-Atlantic Oncology Program study
24. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: A Phase III trial of the Southeastern Cancer Study Group
25. Approaches to the analysis of quality of life data: Experiences gained from a Medical Research Council Lung Cancer Working Party palliative chemotherapy trial
26. A randomised study comparing vincristine, adriamycin, cyclophosphamide to carboplatin, etoposide in previously untreated small cell lung cancer